ストックスクリーナーアプリを入手
52.94
0.04%
0.02
アフターアワーズ：
52.93
-0.010
-0.02%
前日終値:
$52.92
開ける：
$52.92
24時間の取引高:
1.95M
Relative Volume:
0.60
時価総額：
$2.76B
収益：
$190.41M
当期純損益:
$20.48M
株価収益率:
237.61
EPS:
0.2228
ネットキャッシュフロー:
$46.66M
1週間 パフォーマンス:
+0.30%
1か月 パフォーマンス:
+1.32%
6か月 パフォーマンス:
+21.59%
1年 パフォーマンス:
-28.18%
1日の値動き範囲:
$52.90
$52.94
1週間の範囲:
$52.79
$52.94
52週間の値動き範囲:
$29.43
$90.32
Soleno Therapeutics Inc Stock (SLNO) Company Profile
名前
Soleno Therapeutics Inc
セクター
電話
650-213-8444
住所
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLNO
Soleno Therapeutics Inc
|
52.94 | 2.76B | 190.41M | 20.48M | 46.66M | 0.2228 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-18 | 開始されました | Wolfe Research | Outperform |
| 2025-10-07 | 開始されました | Goldman | Buy |
| 2025-08-20 | 開始されました | Wells Fargo | Overweight |
| 2025-06-23 | 開始されました | TD Cowen | Buy |
| 2025-03-05 | 再開されました | Stifel | Buy |
| 2024-12-02 | 繰り返されました | Robert W. Baird | Outperform |
| 2024-12-02 | 繰り返されました | Stifel | Buy |
| 2024-09-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2024-02-05 | 開始されました | Piper Sandler | Overweight |
| 2024-01-23 | 開始されました | Stifel | Buy |
| 2023-11-21 | 再開されました | Guggenheim | Buy |
| 2020-09-29 | 開始されました | Guggenheim | Buy |
| 2020-01-10 | 開始されました | Craig Hallum | Buy |
| 2019-12-23 | 開始されました | Oppenheimer | Outperform |
| 2018-02-13 | 繰り返されました | Maxim Group | Buy |
すべてを表示
Soleno Therapeutics Inc (SLNO) 最新ニュース
FMR LLC increases reported stake in Soleno Therapeutics (NASDAQ: SLNO) - Stock Titan
A Look At Soleno Therapeutics (SLNO) Valuation After Recent Share Momentum And VYKAT XR Launch Progress - simplywall.st
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO - ChartMill
Neurocrine pairs $811M quarter with $2.9B Soleno deal for rare-disease drug - Stock Titan
Neurocrine Biosciences (NBIX) posts strong Q1 2026 results and plans $2.9B Soleno deal - Stock Titan
Big Q1 2026 jump as Neurocrine (NASDAQ: NBIX) inks $2.9B Soleno buy - Stock Titan
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Neurocrine in the spotlight: Can growth justify Soleno bet? By Investing.com - Investing.com UK
SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action - ChartMill
DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of - GlobeNewswire
SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - PR Newswire
SLNO DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts Soleno Therapeutics, Inc. Investors to Participate in the Class Action Lawsuit Today - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors - GlobeNewswire
Soleno Therapeutics 24 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - marketscreener.com
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar - GlobeNewswire
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline - GlobeNewswire Inc.
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Soleno Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
SLNO DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds - The National Law Review
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO - Scott Coop
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - ChartMill
SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Barchart.com
Soleno Therapeutics (SLNO) price target decreased by 15.57% to 57.53 - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Soleno Therapeutics 48 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - ACCESS Newswire
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LL - The National Law Review
SLNO Stockholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, ... - Caledonian Record
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc.SLNO - Business Wire
Soleno Therapeutics Executive Compensation, Corporate Governance, and Pay Practices 2025 - Minichart
Soleno Therapeutics (SLNO) Surges Nearly 60% In April Amid Neurocrine Acquisition Deal - Insider Monkey
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Pictet Asset Management Holding SA Has $28.90 Million Position in Soleno Therapeutics, Inc. $SLNO - MarketBeat
SLNO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Soleno Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SOLENO THERAPEUTICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSLNO - PR Newswire
Neurocrine to acquire Soleno Therapeutics (SLNO) in $53-per-share cash deal - Stock Titan
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
SLNO Shareholders Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
SLNO INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026 - ChartMill
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT - GlobeNewswire
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Allegedly Misrepresenting DCCR Safety Timeline: SueWallSt – Company AnnouncementFT.com - Financial Times
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Hav - GuruFocus
SOLENO DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionSLNO - TMX Newsfile
Soleno Therapeutics Inc (SLNO) 財務データ
収益
当期純利益
現金流量
EPS
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):